-+ 0.00%
-+ 0.00%
-+ 0.00%

NuWays starts Pentixapharm at buy, sets EUR 7.2 price target

PUBT·07/15/2026 07:00:56
Listen to the news
NuWays starts Pentixapharm at buy, sets EUR 7.2 price target
  • NuWays initiated coverage of Pentixapharm with a BUY rating, setting a 12-month target price of EUR 7.2.
  • Thesis centers on PentixaFor, a non-invasive PET scan to subtype primary aldosteronism, positioned as an alternative to adrenal vein sampling.
  • NuWays cited 2025 Endocrine Society guidance recommending hypertension screening, estimating the subtyping-eligible pool rises over 8x to 561,000 patients.
  • The report flagged FDA Fast Track and EMA PRIME status for PentixaFor, describing it as Phase 3-ready.
  • NuWays noted a rights issue targeting about EUR 20 million at EUR 1.85 per share to fund the Phase 3 program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pentixapharm Holding AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_26180) on July 15, 2026, and is solely responsible for the information contained therein.